Redwood Pharma AB
Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.
Redwood Pharma AB (REDW) - Total Assets
Latest total assets as of March 2024: Skr11.68 Million SEK
Based on the latest financial reports, Redwood Pharma AB (REDW) holds total assets worth Skr11.68 Million SEK as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Redwood Pharma AB - Total Assets Trend (2014–2023)
This chart illustrates how Redwood Pharma AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Redwood Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2023)
Redwood Pharma AB's total assets of Skr11.68 Million consist of 33.3% current assets and 66.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 29.6% |
| Accounts Receivable | Skr536.34K | 3.7% |
| Inventory | Skr-536.34 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr6.22 Million | 43.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2023)
This chart illustrates how Redwood Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Redwood Pharma AB's current assets represent 33.3% of total assets in 2023, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 29.6% of total assets in 2023, down from 91.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 43.0% of total assets.
Redwood Pharma AB Competitors by Total Assets
Key competitors of Redwood Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Redwood Pharma AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Redwood Pharma AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Redwood Pharma AB is currently not profitable relative to its asset base.
Redwood Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.49 | 3.25 | 1.06 |
| Quick Ratio | 2.42 | 3.25 | 1.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr723.00K | Skr 3.62 Million | Skr 297.53K |
Redwood Pharma AB - Advanced Valuation Insights
This section examines the relationship between Redwood Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.31 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -20.5% |
| Total Assets | Skr14.48 Million |
| Market Capitalization | $277.13K USD |
Valuation Analysis
Below Book Valuation: The market values Redwood Pharma AB's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Redwood Pharma AB's assets decreased by 20.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Redwood Pharma AB (2014–2023)
The table below shows the annual total assets of Redwood Pharma AB from 2014 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | Skr14.48 Million | -20.52% |
| 2022-12-31 | Skr18.22 Million | -14.14% |
| 2021-12-31 | Skr21.22 Million | +65.15% |
| 2020-12-31 | Skr12.85 Million | -10.90% |
| 2019-12-31 | Skr14.42 Million | -15.23% |
| 2018-12-31 | Skr17.01 Million | +86.97% |
| 2017-12-31 | Skr9.10 Million | -33.97% |
| 2016-12-31 | Skr13.78 Million | +4009.81% |
| 2015-12-31 | Skr335.24K | +211.30% |
| 2014-12-31 | Skr107.69K | -- |